Details of the Drug
General Information of Drug (ID: DM6AYDL)
Drug Name |
2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CHEMBL16709; 54124-67-3; AC1NBNWM; 2-amino-3-methyl-1-(1-pyrrolidinyl)-1-Butanone; SCHEMBL1951493; CTK8J1465; MolPort-004-338-106; ALBB-022686; BDBM50118952; AKOS016347010; AKOS000180650; 1-Pyrrolizino-2-amino-3-methyl-1-butanone; DB-071796; FT-0723537; 2-amino-3-methyl-1-pyrrolidin-1-ylbutan-1-one; F2147-1598; [(1S)-2-methyl-1-(pyrrolidin-1-ylcarbonyl)propyl]amine; 3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-amine hydrochloride; [2-Methyl-1-(pyrrolidin-1-ylcarbonyl)propyl]amine hydrochloride
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 170.25 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||